Antioxidants can help prevent heart attacks, study shows
NEW YORK The bacteria-fighting enzyme that causes nasal mucus to turn green also causes damage during heart attacks, but scientists in Australia may have found a way to control it.
According to published reports, researchers at the University of Sydney’s Heart Research Institute and the Queensland University of Technology have found antioxidants that could control the enzyme myeloperoxidase and stop it from causing damage when white blood cells release it during heart attacks. Normally, the cells dump myeloperoxidase on bacteria to kill them.
The research will appear in Biochemical Journal.
Bausch & Lomb appoints new VP and global president, vision care
ROCHESTER, N.Y. Bausch & Lomb on Monday named Peter Valenti corporate VP and global president, vision care, effective July 1.
Valenti replaces Stuart Heap, who has chosen to step down from his current role with B&L for personal reasons, effective June 30. Heap will remain an active strategic advisor to the company.
“[Valenti] possesses a mix of deep leadership experience, healthcare and eye health expertise, and has already made significant contributions to helping grow the B&L business during his brief tenure,” stated Gerald Ostrov, B&L chairman and CEO. “At the same time, we thank [Heap] for his significant contributions to the company as he chooses to spend more time with his family.”
Valenti joined B&L in January 2009 as president, North America, vision care. Before being named to that role, Valenti served as VP and GM, surgical devices (U.S.), for Covidien, where he led the U.S. sales and marketing strategy for the $1 billion product portfolio from 2007 to 2008.
In conjunction with Valenti’s transition to his new role, the company has named Steven Robins as president, North America, vision care.
Robins joins B&L with approximately two decades of consumer healthcare experience at leading companies such as Johnson & Johnson, Pfizer and Warner Lambert. Most recently, he was GM, Johnson & Johnson Consumer Healthcare Canada, and a VP of the Johnson & Johnson Consumer Group, with responsibility for a number of health and beauty brands such as Listerine, Reach, Band-Aid, Stayfree and Purell.
Herb works as anti-ulcer therapy, study shows
BEIJING A research team led by Syed Rafatullah from Saudi Arabia validated the gastric anti-ulcer properties of the herb Rocket “Eruca sativa L.” (EER) on experimentally-induced gastric secretion and ulceration in albino rats. The study was published April 28 in the World Journal of Gastroenterology.
In recent years, Rocket “Eruca sativa L.” (EER), a member of the Brassicacae family, has gained greater importance as a salad vegetable and spice, especially among Middle Eastern populations and Europeans. It is believed that plants belonging to the Brassicacae family possess diversified medicinal and therapeutic properties including inhibition of tumorigenesis, anti-ulcer and hepatoprotective activities.
Although the introduction of proton-pump inhibitors to the classic anti-ulcer therapy has revolutionized treatment of peptic ulcers and other gastrointestinal disorders, there is still no complete cure for this disease, researchers noted. It has been shown that long term use of these drugs leads to various adverse and side effects. Relapses of the malady, ineffectiveness of different drug regimens and even resistance to drugs are emerging. Thus, there is an urgent requirement to identify more effective and safe anti-ulcer agents.
Researchers found that the ethanolic extract of EER significantly and dose-dependently reduced basal gastric acid secretion, titratable acidity and ruminal ulceration in lab rats. The authors concluded that EER extract possesses anti-ulcer activities against experimentally-induced gastric lesions.